4//SEC Filing
North Annette 4
Accession 0001209191-21-019268
CIK 0001595893other
Filed
Mar 8, 7:00 PM ET
Accepted
Mar 9, 7:26 PM ET
Size
16.8 KB
Accession
0001209191-21-019268
Insider Transaction Report
Form 4
North Annette
EVP, General Counsel & Secty.
Transactions
- Sale
Common Stock
2021-03-08$103.30/sh−500$51,650→ 25,983 total - Sale
Common Stock
2021-03-08$109.89/sh−9,419$1,035,054→ 11,754 total - Sale
Common Stock
2021-03-08$110.77/sh−4,571$506,330→ 7,183 total - Exercise/Conversion
Common Stock
2021-03-08$17.00/sh+20,000$340,000→ 26,483 total - Sale
Common Stock
2021-03-08$109.09/sh−4,810$524,723→ 21,173 total - Sale
Common Stock
2021-03-08$111.69/sh−700$78,183→ 6,483 total - Exercise/Conversion
Stock Option (right to buy)
2021-03-08−20,000→ 175,491 totalExercise: $17.00Exp: 2029-04-14→ Common Stock (20,000 underlying)
Footnotes (6)
- [F1]Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on November 16, 2020.
- [F2]The weighted average sale price for the transaction reported was $109.09, and the range of prices were between $108.46 and $109.41. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
- [F3]The weighted average sale price for the transaction reported was $109.89, and the range of prices were between $109.47 and $110.47. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
- [F4]The weighted average sale price for the transaction reported was $110.77, and the range of prices were between $110.48 and $111.47. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
- [F5]The weighted average sale price for the transaction reported was $111.69, and the range of prices were between $111.52 and $111.89. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
- [F6]One-fourth of the option vested on April 15, 2020. Thereafter, 1/48th of the Option vests on a monthly basis over 36 months until the option becomes fully vested.
Documents
Issuer
Turning Point Therapeutics, Inc.
CIK 0001595893
Entity typeother
Related Parties
1- filerCIK 0001341011
Filing Metadata
- Form type
- 4
- Filed
- Mar 8, 7:00 PM ET
- Accepted
- Mar 9, 7:26 PM ET
- Size
- 16.8 KB